Recent

% | $
Quotes you view appear here for quick access.

Best Buy Co., Inc. Message Board

uncle.bubs 13 posts  |  Last Activity: May 25, 2016 7:18 PM Member since: Apr 20, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Sydys Corp. Announces Publication of Phase 2b CVac(TM) Data Against Ovarian Cancer in Journal for ImmunoTherapy of Cancer

    Data Demonstrate Significant Overall and Progression Free Survival Improvements in Second Remission Ovarian Cancer Patients

    SEATTLE, May 18, 2016 (GLOBE NEWSWIRE) -- Sydys Corporation (OTCQB:SYYC), a clinical stage biotechnology company focused on the development of immunotherapies, today announced the publication of findings from a study demonstrating the potential of CVac(TM) in ovarian cancer in the Journal for ImmunoTherapy of Cancer.

    The study entitled "Progression-free and overall survival in ovarian cancer patients treated with CVac(TM), a mucin 1 dendritic cell therapy in a randomized Phase 2b trial was led by Dr Heidi Gray at the University of Washington Medical Center, WA, USA with Dr Jeffrey C Goh of Greenslopes Private Hospital, Queensland, Australia and included several universities and institutions in the United States and Australia (NCT01068509), including;
    -- Scripps Cancer Center, San Diego, CA

    -- Peter MacCallum Cancer Centre, East Melbourne Vic, Australia

    -- Cleveland Clinic Foundation, Cleveland, OH

    -- Duke Cancer Institute, Duke University Health System, Durham, NC

    -- University of California, San Francisco & Sutter Health Research
    Institute, San Francisco, CA

    -- Stanford University Cancer Institute, Stanford, CA

    The publication outlines results obtained from a Phase 2b clinical trial evaluating the safety, efficacy and immune outcomes of CVac(TM) in patients with advanced epithelial ovarian cancer.

    The randomized, open label trial enrolled 56 patients undergoing first or second clinical remission. Twenty seven patients received the standard of care, while 20 patients received CVac(TM), a mucin 1 targeted-dendritic cell (DC) treatment as a maintenance therapy, over a period of 56 weeks. The primary endpoint was efficacy measure through progression free survival (PFS), while the secondary endp

    Sentiment: Strong Buy

  • Reply to

    I love when lots of new bashes show up......

    by uncle.bubs May 15, 2016 4:57 PM
    uncle.bubs uncle.bubs May 15, 2016 7:32 PM Flag

    The stock of Prima Biomed Limited Ads (NASDAQ:PBMD) registered a decrease of 19.75% in short interest. PBMD’s total short interest was 511,700 shares in May as published by FINRA. Its down 19.75% from 637,600 shares, reported previously. With 94,200 shares average volume, it will take short sellers 5 days to cover their PBMD’s short positions. The short interest to Prima Biomed Limited Ads’s float is 0.83%. The stock decreased 2.50% or $0.024 on May 11, hitting $0.941. About 124,499 shares traded hands. Prima BioMed Ltd (ADR) (NASDAQ:PBMD) has declined 15.65% since October 5, 2015 and is downtrending. It has underperformed by 20.55% the S&P500.

    Prima BioMed Limited is an Australia biotechnology company. The company has a market cap of $66.32 million. The Firm is engaged in research, development and commercialization of licensed medical biotechnology. It currently has negative earnings. The Firm focuses on cancer immunotherapy research.

    Out of 4 analysts covering Prima Biomed (NASDAQ:PBMD), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Prima Biomed has been the topic of 4 analyst reports since October 14, 2015 according to StockzIntelligence Inc.

    According to TipRanks which ranks over 7,500 financial analysts and bloggers based on how well their calls perform, the analyst consensus on Prima Biomed is Moderate Buy . The data is based on 2 analysts that rated Prima Biomed in the last 3 months.

  • Tells me boiler plate wannabees are trying to steal shares cheap! Not mine wannabees not mine.....! $$$$$$$$$

    Sentiment: Strong Buy

  • uncle.bubs uncle.bubs Apr 20, 2016 7:13 PM Flag

    This came off my Ameritrade account news today, thus the rise in volume and share price. I have no idea why its not out on the standard news wire I would guess it will be out tonight or in the A.M.

    Sentiment: Strong Buy

  • uncle.bubs uncle.bubs Apr 20, 2016 1:35 PM Flag

    LOL boy do you look Dumb right now...

    Ameritrade: Prima Biomeds Data from Partnership with Japans NEC & Yamaguchi University shows potential in Solid Cancer Vaccine, IMP321 Effective.

    Sentiment: Strong Buy

  • Reply to

    News is out solid cancer vaccine

    by uncle.bubs Apr 20, 2016 11:22 AM
    uncle.bubs uncle.bubs Apr 20, 2016 1:33 PM Flag

    Ameritrade: Prima Biomeds Data from Parnership with Japans NEC & Yamaguchi University shows potential in Solid Cancer Vaccine, IMP321 Effective.

    Sentiment: Strong Buy

  • Ameritrade: Prima Biomeds Data from Parnership with Japans NEC & Yamaguchi University shows potential in Solid Cancer Vaccine, IMP321 Effective.

    That's the news!

    Sentiment: Strong Buy

  • News is out solid cancer vaccineit's on Ameritrade's website but I'm unable to copy and paste

  • uncle.bubs uncle.bubs Apr 19, 2016 6:53 PM Flag

    Patience Longs good news is coming the company will have an update soon and in my opinion the share price will hit the targets

    Sentiment: Strong Buy

  • Maxim Group Begins Coverage on Prima BioMed Ltd (PBMD)

    Investment analysts at Maxim Group initiated coverage on shares of Prima BioMed Ltd (NASDAQ:PBMD) in a research note issued on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $4.00 price target on the stock. Maxim Group’s price objective indicates a potential upside of 339.56% from the company’s previous close.
    Prima BioMed (NASDAQ:PBMD) traded down 0.55% during mid-day trading on Monday, reaching $0.91. The company’s stock had a trading volume of 142,637 shares. Prima BioMed has a 1-year low of $0.42 and a 1-year high of $6.48. The firm has a 50 day moving average price of $0.92 and a 200-day moving average price of $1.05. The company’s market capitalization is $59.42 million.
    Several other equities research analysts have also weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $3.00 price objective on shares of Prima BioMed in a research note on Monday, March 7th. Roth Capital started coverage on Prima BioMed in a research note on Wednesday, December 30th. They issued a “buy” rating and a $6.00 price objective on the stock. FBR & Co. reiterated an “outperform” rating on shares of Prima BioMed in a research note on Thursday, January 28th. Finally, Zacks Investment Research lowered Prima BioMed from a “hold” rating to a “sell” rating in a research note on Saturday, March 5th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $4.75.


    Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the

    Sentiment: Strong Buy

  • WASHINGTON — Cancer immunotherapy will get a hefty dose of its own moonshot Wednesday when a tech billionaire announces he's giving $250 million to six cancer centers nationwide, including Manhattan's Memorial Sloan Kettering and Stanford.

    Sean Parker, founder of the music file-sharing service Napster and the founding president of Facebook, says he is putting his money behind cancer immune therapy because it is at a turning point and would benefit from research that is done without regard for the costs.

    Immunotherapy, which enhances the body's immune system to kill cancer cells, is best known these days because former president Jimmy Carter was on an immune-based drug treatment when he announced in December that there is no detectable cancer in his body.

    Parker's enormous cash infusion is the largest ever for cancer immunotherapy — and one of the largest ever for cancer research — and comes three months after President Obama called for a $1 billion federal cancer research program that he dubbed a “moonshot." The estate of the billionaire shipping magnate Daniel Ludwig donated $540 million to six cancer centers in 2014 and Nike co-founder Phil Knight pledged $500 million to cancer researchers at Oregon Health & Science University in 2013.

    Last month, former New York City mayor Michael Bloomberg, Jones Apparel Group founder Sidney Kimmel and other philanthropists announced a $125 million donation for cancer immunotherapy research for the Johns Hopkins University medical school.

    The new Parker Institute for Cancer Immunotherapy in San Francisco will fund "high risk best ideas that may not get funded by the government," says Jeffrey Bluestone, a prominent immunologist and former University of California, San Fra

    Sentiment: Strong Buy

BBY
32.03+0.080(+0.25%)May 27 4:00 PMEDT